{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:22:22Z","timestamp":1788985342774,"version":"build-2803163510"},"reference-count":69,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation of Korea (NRF)","award":["RS-2024-00347600"],"award-info":[{"award-number":["RS-2024-00347600"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Deucravacitinib is an allosteric, selective tyrosine kinase 2 (TYK2) inhibitor that has demonstrated significant efficacy in the treatment of psoriasis. TYK2, a member of the Janus kinase (JAK) family, plays a critical role in intracellular signaling pathways for pro-inflammatory cytokines. Unlike traditional JAK inhibitors, which target active domains, deucravacitinib selectively binds to the pseudokinase domain of TYK2. This binding induces a conformational change that locks the enzyme in an inactive state, ensuring superior selectivity for TYK2 over JAK 1\/2\/3. This unique mechanism specifically inhibits key pro-inflammatory cytokines, including IL-12, IL-23, and type I interferons, critical in the pathogenesis of psoriasis and other immune-mediated diseases. As a result, deucravacitinib represents a promising option for targeted therapy in immune-mediated diseases and may reduce adverse events commonly associated with broader immunosuppressive treatments. Furthermore, its oral administration offers a convenient alternative to injectable biologics, potentially improving patient adherence and treatment satisfaction. This review highlights recent studies suggesting that deucravacitinib may also have therapeutic benefits in psoriatic arthritis, palmoplantar pustulosis, systemic lupus erythematosus, Sjogren\u2019s disease, and inflammatory bowel disease. Given its expanding therapeutic potential, deucravacitinib may provide a safer and more effective alternative to current therapies, offering a tailored approach to treatment.<\/jats:p>","DOI":"10.3390\/jcm14051745","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:54:38Z","timestamp":1741154078000},"page":"1745","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Expanding Therapeutic Potential of Deucravacitinib Beyond Psoriasis: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6246-0331","authenticated-orcid":false,"given":"Chul-Hwan","family":"Bang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3099-4109","authenticated-orcid":false,"given":"Chul-Jong","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bucheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 14647, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Seob","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bucheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 14647, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"ref_1","first-page":"S713","article-title":"Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors","volume":"14","author":"Salas","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"117114","DOI":"10.1016\/j.ejmech.2024.117114","article-title":"Tyrosine kinase 2 inhibitors: Synthesis and applications in the treatment of autoimmune diseases","volume":"283","author":"Pan","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rusi\u00f1ol, L., and Puig, L. (2023). Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043391"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.immuni.2009.03.013","article-title":"Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12","volume":"30","author":"Schulz","year":"2009","journal-title":"Immunity"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., and Guggino, G. (2021). Role of the IL-23\/IL-17 Pathway in Rheumatic Diseases: An Overview. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.637829"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1189\/jlb.3A1013-541R","article-title":"Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27","volume":"96","author":"Bosmann","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human Tyrosine Kinase 2 Deficiency Reveals Its Requisite Roles in Multiple Cytokine Signals Involved in Innate and Acquired Immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.4049\/jimmunol.176.12.7263","article-title":"Tyk2 Negatively Regulates Adaptive Th1 Immunity by Mediating IL-10 Signaling and Promoting IFN-\u03b3-Dependent IL-10 Reactivation1","volume":"176","author":"Shaw","year":"2006","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 Plays a Restricted Role in IFN\u03b1 Signaling, Although It Is Required for IL-12-Mediated T Cell Function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1\/2\/3 Inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s13555-023-01034-7","article-title":"Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52\u2009weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","unstructured":"(2025, February 20). Available online: https:\/\/news.bms.com\/news\/corporate-financial\/2025\/New-Five-Year-Sotyktu-deucravacitinib-Data-Show-Consistent-Safety-and-Durable-Response-Rates-in-Moderate-to-Severe-Plaque-Psoriasis\/default.aspx."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Boutet, M.A., Nerviani, A., Gallo Afflitto, G., and Pitzalis, C. (2018). Role of the IL-23\/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020530"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: A systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kavanaugh, A., Coates, L.C., Mease, P.J., Nowak, M., Hippeli, L., Lehman, T., Banerjee, S., and Merola, J.F. (2024). Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial. Rheumatology, keae580.","DOI":"10.1093\/rheumatology\/keae580"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/art.42921","article-title":"Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated with Disease Activity, Pharmacodynamics, and Clinical Responses","volume":"76","author":"FitzGerald","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_30","unstructured":"(2025, February 20). Available online: https:\/\/news.bms.com\/news\/details\/2024\/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Two-Pivotal-Phase-3-Trials-Evaluating-Sotyktu-deucravacitinib-in-Adults-with-Psoriatic-Arthritis\/default.aspx."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","article-title":"Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments","volume":"21","author":"Zozula","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","article-title":"Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial","volume":"155","author":"Terui","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/1346-8138.16667","article-title":"Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study","volume":"50","author":"Yamanaka","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"590","DOI":"10.25259\/IJDVL_775_2023","article-title":"Comparative efficacy and safety of JAK\/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis","volume":"90","author":"Zheng","year":"2024","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Du, N., Yang, J., Zhang, Y., Lv, X., Cao, L., and Min, W. (2024). Successful treatment of refractory palmoplantar pustulosis by upadacitinib: Report of 28 patients. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1476793"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2399220","DOI":"10.1080\/09546634.2024.2399220","article-title":"Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis","volume":"35","author":"Papara","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic Lupus Erythematosus: A Review","volume":"331","author":"Siegel","year":"2024","journal-title":"Jama"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","article-title":"Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New","volume":"7","author":"Basta","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/rheumatology\/keaa267","article-title":"Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls","volume":"60","author":"Bultink","year":"2021","journal-title":"Rheumatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","article-title":"\u2019Not at target\u2019: Prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study","volume":"24","author":"Louthrenoo","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103723","DOI":"10.1016\/j.autrev.2024.103723","article-title":"Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules\u2014A systematic review and meta-analysis","volume":"24","author":"Bokor","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren\u2019s syndrome: A systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Holdgate, N., and St Clair, E.W. (2016). Recent advances in primary Sjogren\u2019s syndrome. F1000Research, 5.","DOI":"10.12688\/f1000research.8352.1"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ma, D., Feng, Y., and Lin, X. (2024). Immune and non-immune mediators in the fibrosis pathogenesis of salivary gland in Sj\u00f6gren\u2019s syndrome. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1421436"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41584-023-00932-6","article-title":"Genetics and epigenetics of primary Sj\u00f6gren syndrome: Implications for future therapies","volume":"19","author":"Thorlacius","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Bombardieri","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zhang, W., Zhong, G., Ren, X., and Li, M. (2024). Research progress of Ustekinumab in the treatment of inflammatory bowel disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1322054"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Fanizza, J., D\u2019Amico, F., Lusetti, F., Fasulo, E., Allocca, M., Furfaro, F., Zilli, A., Parigi, T.L., Radice, S., and Peyrin-Biroulet, L. (2023). The Role of IL-23 Inhibitors in Crohn\u2019s Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010224"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00535-024-02130-x","article-title":"Immunity in digestive diseases: New drugs for inflammatory bowel disease treatment-insights from Phase II and III trials","volume":"59","author":"Massironi","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn\u2019s Disease","volume":"391","author":"Chapman","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: Maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): Phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"i091","DOI":"10.1093\/ecco-jcc\/jjab232.081","article-title":"DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study","volume":"16","author":"Danese","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cassalia, F., and Belloni Fortina, A. (2024). Psoriasis in women with psoriatic arthritis: Hormonal effects, fertility, and considerations for management at different stages of life. Reumatismo, 76.","DOI":"10.4081\/reumatismo.2024.1775"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11926-024-01169-2","article-title":"Incremental Cardiovascular Risk of Menopause in Women with Psoriasis, Psoriatic Arthritis or Spondyloarthritis?","volume":"27","author":"Vegt","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bucur, \u0218., Savu, A.P., St\u0103nescu, A.M.A., \u0218erban, E.D., Nicolescu, A.C., Constantin, T., Bobirc\u0103, A., and Constantin, M.M. (2022). Oversight and Management of Women with Psoriasis in Childbearing Age. Medicina, 58.","DOI":"10.3390\/medicina58060780"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Simionescu, A.A., Danciu, B.M., and Stanescu, A.M.A. (2021). State-of-the-Art Review of Pregnancy-Related Psoriasis. Medicina, 57.","DOI":"10.3390\/medicina57080804"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/bjd.18164","article-title":"Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population","volume":"181","author":"Carretero","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_69","unstructured":"(2025, February 20). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214958s000lbl.pdf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1745\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:28Z","timestamp":1760028448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":69,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051745"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051745","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]}}}